SAN FRANCISCO, June 21, 2023 /PRNewswire/ — Qardio, a leading innovator in healthcare technology, has proudly unveiled its groundbreaking Livestream solution suite, which includes continuous ECG, Blood Pressure, Pulse Oximetry (SPO2), Body Temperature, Weight, and Body Position monitoring, marking a significant leap forward in real-time virtual patient care. These cutting-edge real-time solutions have […]
Other News
BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study
SUNNYVALE, Calif., June 20, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that FDA Center for Biologics Evaluation and Research (CBER) has completed review of the CardiAMP Cell Therapy System adaptive statistical analysis design supplement […]
ZyVersa Therapeutics Announces a Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arteries of Patients with Peripheral Arterial Disease (PAD)
PAD, characterized by vascular inflammation and associated calcification, affects 8.5 million people in the United States and contributes to more than 50,000 limb amputations annually, yet there are no specific pharmacologic treatments ZyVersa is developing Inflammasome ASC Inhibitor IC 100 for numerous inflammatory diseases WESTON, Fla., June 20, 2023 (GLOBE […]
Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)
— VASCEPA® Approved in KSA To Reduce the Risk of Cardiovascular (CV) Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT– — VASCEPA Becomes First and Only Approved Medication in KSA for Reducing CV Risk […]
Laguna Tech USA Announces Successful Heart Valve Procedure in First-in-Human Clinical Trial of Innovative ALPHA Aortic Valve
Patient with aortic regurgitation achieves complete resolution of regurgitation immediately following procedure, which was maintained at the 30-day follow up First-in-class, low profile one-piece self-expanding ALPHA Aortic Valve System engineered to optimize positioning and placement of valve using a percutaneous transfemoral approach Versatile design of valve and delivery system expected […]
Cardio Diagnostics Holdings, Inc Democratizes CHD Detection with Nationwide Launch of PrecisionCHD™
Coronary Heart Disease Detection Test Merges Epigenetic and Genetic Biomarkers with Artificial Intelligence, Offering Remote and Scalable Deployment Capabilities Across the Nation CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer in AI-driven precision cardiovascular medicine tests, today announces the nationwide launch of PrecisionCHD™. This groundbreaking test marks a significant […]
Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
Developed in collaboration with Mayo Clinic, with support from Pfizer, this ECG-AI algorithm aims to aid physicians in earlier identification of cardiac amyloidosis CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana, Inc., a leading AI-driven health technology company, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its ECG-AI algorithm […]
Cleerly Wins 2023 Artificial Intelligence Breakthrough Award
Prestigious International Annual Awards Program Honors Standout AI and Machine Learning Solutions and Companies DENVER–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care for heart disease, today announced that it has been named “Best Overall AI Solution” in the sixth annual AI Breakthrough Awards program conducted by AI Breakthrough, a […]
DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the U.S. Food and Drug Administration (FDA) has removed the clinical hold placed on the investigational new drug application for its ReMEDy2 phase 2/3 clinical trial […]
DiaMedica Therapeutics Announces $37.5 Million Private Placement
MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases (“DiaMedica” or the “Company”), today announced it has entered into definitive agreements to sell its common shares in a private placement with accredited investors. The transaction is expected to […]



